Skip to Content
Is it Exocrine Pancreatic Insufficiency? Get more info

Tagamet HB (cimetidine) Disease Interactions

There are 4 disease interactions with Tagamet HB (cimetidine):

Major

Cimetidine (Includes Tagamet HB) ↔ Liver Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Cimetidine is partially metabolized by the liver, and to a greater extent when administered orally than when given intravenously. Although dosage reductions are generally not necessary, therapy with cimetidine should be administered cautiously in patients with liver disease. Hepatotoxicity has been associated with cimetidine use. In addition, liver disease appears to be a risk factor for cimetidine-related central nervous system toxicity, which may include mental confusion, agitation, psychosis, depression, anxiety, hallucinations, and disorientation. These effects are usually reversible within 3 to 4 days after discontinuation of therapy.

References

  1. Taylor DC, Cresswell PR, Bartlett DC "The metabolism and elimination of cimetidine, a histamine H2-receptor antagonist, in the rat, dog and man." Drug Metab Dispos 6 (1978): 21-30
  2. Grahnen A, Jameson S, Loof L, Tyllstrom J, Lindstrom B "Pharmacokinetics of cimetidine in advanced cirrhosis." Eur J Clin Pharmacol 26 (1984): 347-55
  3. Hashimoto F, Davis RL, Egli D "Hepatitis following treatments with famotidine and then cimetidine." Ann Pharmacother 28 (1994): 37-9
View all 14 references
Major

H2 Antagonists (Includes Tagamet HB) ↔ Gi Bleeding

Severe Potential Hazard, Moderate plausibility

Applies to: Gastrointestinal Hemorrhage

Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.

Moderate

Cimetidine (Includes Tagamet HB) ↔ Hemodialysis

Moderate Potential Hazard, High plausibility

Applies to: hemodialysis

Cimetidine is partially removed by hemodialysis and should be administered after dialysis.

References

  1. Larsson R, Erlanson P, Bodemar G, Norlander B, Fransson L, Strouth L "Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis." Eur J Clin Pharmacol 21 (1982): 325-30
  2. Bjaeldager PA, Jensen JB, Nielsen LP, Larsen NE, Hvidberg EF "Pharmacokinetics of cimetidine in patients undergoing hemodialysis." Nephron 34 (1983): 159-63
  3. Pizzella KM, Moore MC, Schultz RW, Walshe J, Schentag JJ "Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion." Ther Drug Monit 2 (1980): 273-81
View all 4 references
Moderate

Cimetidine (Includes Tagamet HB) ↔ Renal Dysfunction

Moderate Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Cimetidine and its metabolites are primarily eliminated by the kidney. The daily dosage should initially be reduced in patients with moderate to severe renal impairment (CrCl < 50 mL/min). If necessary, the daily dosage may be increased with caution. Renal dysfunction also appears to be a risk factor for cimetidine-related central nervous system toxicity, which may include mental confusion, agitation, psychosis, depression, anxiety, hallucinations, and disorientation. These effects are generally reversible within 3 to 4 days after discontinuation of therapy.

References

  1. Larsson R, Bodemar G, Kagedal B "The effect of cimetidine, a new histamine H2-receptor antagonist, on renal function." Acta Med Scand 205 (1979): 87-9
  2. "Product Information. Tagamet (cimetidine)." SmithKline Beecham, Philadelphia, PA.
  3. Guay DR, Matzke GR, Bockbrader HN, Dancik J "Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function." Clin Pharm 2 (1983): 157-62
View all 7 references

Tagamet HB (cimetidine) drug Interactions

There are 748 drug interactions with Tagamet HB (cimetidine)

Tagamet HB (cimetidine) alcohol/food Interactions

There are 3 alcohol/food interactions with Tagamet HB (cimetidine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide